Antengene Corporation Limited (HK:6996) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Antengene Corporation Limited has announced the approval of XPOVIO® as a new treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma in China. This marks a significant milestone for the company, enhancing its portfolio in the realm of hematology oncology treatments. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.